Clinical trial
A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer
NCT03051659
Study timeline
Study start (actual)2017-03-22Date precision: day
Registry last updated2024-03-06
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancerunresolved
Interventions
Eribulin MesylateDRUG · verified · RxNorm: eribulin mesylate
PembrolizumabDRUG · verified · RxNorm: pembrolizumab
Sponsors & collaborators
Dana-Farber Cancer Institutelead sponsor
Merck Sharp & Dohme LLCcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03051659 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.